BUZZ - Trimble shares fall due to missed Q3 revenue expectations and slowing ARR growth
路透社2026/11/04 14:06November 4 - ** Navigation equipment manufacturer Trimble (TRMB.O) saw its share price fall 9.6% in premarket trading to $59.28
** (link) Reported third quarter revenue of $966.8 million, below analysts' expectations of $972.6 million
** The company expects fiscal 2026 revenue to be between $3.91 billion and $3.94 billion, previously forecast at $3.90 billion to $3.95 billion
** The report shows that third quarter annual recurring revenue grew 11% year-on-year, down from 14% in the previous quarter
** Out of 15 brokerages, 14 rate the stock as "buy" or higher, and one rates it as "hold"; the median target price is $76 — LSEG data
** As of the close of the previous trading day, the stock had fallen 16.3% year to date
(To facilitate non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the translated text and provides the automated translations solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of this translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
